SA
PTCT icon

Sacks & Associates’s PTC Therapeutics PTCT Stock Holding History

Sacks & Associates’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$263K Hold
3,869
– – 0.18% 74
2026
Q1 		$264K Hold
3,869
– – 0.2% 70
2025
Q4 		$294K Buy
+3,869
New +$281K 0.22% 67

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Sacks & Associates's PTCT Position: Q2 2026 in Review

Sacks & Associates held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 3,869 shares worth $263K. The position accounts for 0.18% of the portfolio, ranked #74.

Sacks & Associates first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. The position peaked at $294K in Q4 2025. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Sacks & Associates held 3,869 shares of PTC Therapeutics worth $263K as of Q2 2026.
  • Sacks & Associates left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up 0.18% of Sacks & Associates's portfolio in Q2 2026, its #74 holding.
  • Sacks & Associates first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Sacks & Associates's PTC Therapeutics position peaked at $294K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Sacks & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.